NYSE$MD
Pediatrix Medical Group, Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Pediatrix reported solid patient volumes, stable payor mix, and reduced overhead, counterbalanced by continuing underperformance by their revenue cycle management vendor.
Pediatrix Medical Group reported Q4 2022 results with a net revenue of $514 million, income from continuing operations of $36 million, and Adjusted EBITDA of $66 million. Adjusted EPS from continuing operations was reported at $0.47 per share.
- Net revenue for the quarter was $514 million.
- Income from continuing operations was $36 million.
- Adjusted EBITDA was $66 million.
- Adjusted EPS from continuing operations was $0.47.
Headline financials
Revenue & EPS history
Pediatrix · Revenue · Quarterly
$514M
Forward guidance
Pediatrix anticipates that its 2023 Adjusted EBITDA will be in a range of $235 million to $245 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
34 / 68 earnings
Positive
+31.3%
Q3 2020
Best reaction
-24.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.3% | +5.2% | +0.0% | |
| Q4 2025 | -12.2% | -8.7% | -10.3% | |
| Q3 2025 | +21.3% | +29.2% | +37.2% | |
| Q1 2025 | +12.1% | +12.2% | +7.5% | |
| Q4 2024 | +22.1% | +9.1% | +0.7% | |
| Q3 2024 | +22.9% | +30.5% | +21.4% | |
| Q2 2024 | +26.4% | +31.5% | +40.9% | |
| Q1 2024 | -8.4% | -11.4% | -25.8% | |
| Q4 2023 | -6.8% | -5.4% | +0.6% | |
| Q3 2023 | -11.7% | -11.8% | -21.8% | |
| Q2 2023 | +5.9% | +6.4% | +1.2% | |
| Q1 2023 | -2.4% | -4.5% | -5.4% | |
| Q4 2022 | +4.6% | +5.8% | -5.0% | |
| Q3 2022 | -16.2% | -18.3% | -12.6% | |
| Q2 2022 | -12.1% | -7.8% | -22.1% | |
| Q1 2022 | -18.5% | -16.6% | -14.4% | |
| Q4 2021 | -9.2% | -8.9% | -6.9% | |
| Q3 2021 | -1.2% | -3.3% | -10.7% | |
| Q2 2021 | +7.9% | +11.4% | +2.1% | |
| Q1 2021 | +19.5% | +14.8% | +19.4% | |
| Q4 2020 | -20.5% | -16.8% | -0.9% | |
| Q3 2020 | +31.3% | +32.0% | +60.5% | |
| Q2 2020 | -1.3% | -1.3% | -4.6% | |
| Q1 2020 | +5.6% | -0.7% | +38.7% | |
| Q4 2019 | -24.8% | -30.0% | -64.6% | |
| Q3 2019 | +14.6% | +18.1% | +18.9% | |
| Q2 2019 | -9.1% | -13.6% | -14.2% | |
| Q1 2019 | +3.8% | +3.8% | -12.7% | |
| Q4 2018 | -4.2% | -5.9% | -18.3% | |
| Q3 2018 | -5.0% | -4.4% | -2.6% | |
| Q2 2018 | +10.1% | +13.3% | +10.4% | |
| Q1 2018 | -4.4% | -3.6% | -1.4% | |
| Q4 2017 | +6.6% | +6.7% | +13.8% | |
| Q3 2017 | -4.9% | +0.1% | +15.6% | |
| Q2 2017 | -16.8% | -20.4% | -21.7% | |
| Q1 2017 | -8.5% | -9.9% | -8.2% | |
| Q4 2016 | -3.5% | -1.3% | +1.1% | |
| Q3 2016 | -6.3% | -6.3% | +1.3% | |
| Q2 2016 | -8.5% | -10.8% | -16.7% | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | +4.2% | — | — | |
| Q1 2015 | -1.2% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | +10.2% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q4 2013 | +5.0% | — | — | |
| Q3 2013 | +2.4% | — | — | |
| Q2 2013 | +1.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +7.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | -6.6% | — | — | |
| Q4 2011 | -1.7% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -0.9% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2011 | +4.5% | — | — | |
| Q4 2010 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — | |
| Q3 2009 | +2.0% | — | — | |
| Q3 2010 | +2.0% | — | — | |
| Q2 2010 | +2.3% | — | — | |
| Q4 2009 | +2.3% | — | — | |
| Q2 2009 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro